MSD

News

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st

News

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.

News

Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia

MSD starts second phase 3 of Imago drug for blood cancers

MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M

News

With FDA okay, AZ takes on MSD in early-stage lung cancer

AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.

News